The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT
Age≥18 years old;
Clinically diagnosed as acute ischemic stroke and received standard dose (0.25mg/kg) of tenecteplase IVT within 4.5 hours of onset;
Total National Institute of Health stroke scale (NIHSS)≥4 or single limb motor item score≥2, and total NIHSS≤15 after IVT;
Tirofiban or placebo treatment can be initiated within 6h after IVT;
Received or plan to undergo bridge therapy;
Large area of infarct indicated by radiological imaging(≥1/3 of middle cerebral artery supply area);
Atrial fibrillation or suspected cardiac embolism;
Accompanied by epileptic seizures;